Medical technology company BD (Becton, Dickinson and Company) (NYSE:BDX) said on Thursday that it has passed the US Food and Drug Administration's 510(k) clearance for its second generation BD Nano pen needle for people living with diabetes, with commercial availability in mid-2019.

The company added the BD Nano 2nd gen pen needles offer people who inject diabetes medications a more reliable subcutaneous delivery of their medication to better manage their diabetes. The second gen pen needles help mitigate the risks resulting from user injection force variability through its contoured needle base to support more reliable 4 mm target injection depth compared to other 4mm pen needles.

According to the company, the new upgraded design has demonstrated more reliable subcutaneous injection depth resulting in up to an eight fold reduction in calculated intramuscular injection risk. The new ergonomic design makes it easier to use, from attachment to disposal, compared to other pen needles.

This latest advancement to the company's BD Nano portfolio includes all the benefits its predecessor pen needle. The proper injection technique is critical to insulin's consistent absorption. It can inhibit predictable insulin uptake, including accidental intramuscular injections, which can be caused by greater than required injection force.

In conjunction, the recent updates to the 2019 American Diabetes Association (ADA) Standards of Care highlight the importance of proper injection technique as part of good diabetes management, concluded the company.